View All Reports Email Us

Global Women Healthcare Market Research Report- Forecast To 2023 Global Women Healthcare Market Research Report- Forecast To 2023

  • ID: MRFR/HC/2248-CRR
  • |
  • June, 2017
  • |
  • Region: Global
  • |
  • 130 pages
  • |
  • Cooked Research Reports

Global Women Healthcare Market Information; by Indication (Postmenopausal Osteoporosis, Infertility, Reproductive Health Management, Polycystic Ovary Syndrome, Gynecologic Cancer and others) by diagnosis and treatment; Diagnosis (Bone Densitometry, Diagnostic Imaging Tests, Biopsies, Ovulation Testing and others), Treatment (Therapeutics, surgeries and others) by End users (Hospitals & Clinics, Gynecology Centers, Research Institutes, and others) - Forecast to 2023


Market Synopsis of Global Women Healthcare market:


Market Scenario:


Women health is referred to the health problems that are specific to women anatomy. It relates to the unique issues which includes pregnancy, menopause, and conditions of the female organs. Women health also includes medical situations in which women face problems not directly related to their biology but due to gender-differentiated access to medical treatment. Women's health issues have attained higher international perceptibility in the recent decades. The targeted policies and government initiatives to decrease the burden of the women health diseases have enabled women to lead healthier lives, while some significant gender-based health disparities remain in many countries. With limited awareness and less income levels in many developing countries are making health improvements for women exceptionally difficult.


The market for women healthcare is projected to grow at a steady CAGR of 5.04% during the forecast period from 2017-2023.


Research Methodology

Research Methodology of Women Healthcare market


Source: WHO (World Health Organization), CDC (Centre for Disease Control and Prevention), Food and Drug Administration (FDA), NHS (National Health Services),Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Intended Audience



  • Women Healthcare products manufacturers & suppliers

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Academic institutes and universities


Figure 1           Global Women Healthcare Market by Indications, 2016 (%)

Global Women Healthcare Market by Indications, 2016


Segments:


The Women Healthcare Market is segmented on the basis of indications, diagnosis and treatment and also on the basis of end users. Based on the indications, the market has been segmented as postmenopausal osteoporosis, infertility, reproductive health management, polycystic ovary syndrome, gynecologic cancer and others. Gynecologic cancer segment has been further divided into breast, ovarian or other types of cancer. On the basis of diagnosis the market has been segmented as bone densitometry, diagnostic imaging tests, biopsies, ovulation testing and others. Similarly, on the basis of treatment the market has been classified as therapeutics, surgeries and others. Lastly on the basis of end users the market has been further classified into hospitals & clinics, gynecology centers, research institutes, and others


 


Regional analysis


On the basis of region the market is segmented into North America, Europe, Asia-Pacific and Middle East and Africa. North America was commands the largest market share which is expected to reach USD 21,782.6 million by 2023 due to well-developed economy and initiatives taken to promote women healthcare in the region. On the other hand factors such as high cost of diagnosis and treatments are restricting the market growth in the Middle East & African region, while Asia-Pacific countries are expected to be the fastest growing region with a CAGR of 5.46% from 2017-2023.  


Market players of Global Women Healthcare Industry:


Market players of Canadian healthcare industries are Allergan plc. (Ireland), Amgen (California), Bayer A G (Germany), Becton Dickinson and Company (U.S.), Eli Lilly Company (U.S.), Merck & Co., Inc., (U.S.), Pfizer Inc., (U.S.), and Teva Pharmaceuticals (Israel).

The report for Global women Healthcare Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Table of Contents                          

                               

1              REPORT PROLOGUE       

2              MARKET INTRODUCTION             

2.1          INTRODUCTION              

2.2          SCOPE OF STUDY            

2.3          RESEARCH OBJECTIVE    

2.4          ASSUMPTIONS & LIMITATIONS 

2.4.1       ASSUMPTIONS 

2.4.2       LIMITATIONS    

2.5          MARKET STRUCTURE     

3              RESEARCH METHODOLOGY        

3.1          RESEARCH PROCESS       

3.2          PRIMARY RESEARCH       

3.3          SECONDARY RESEARCH

4              MARKET DYNAMICS       

4.1          INTRODUCTION              

4.2          DRIVERS              

4.2.1       INCREASING POOR HEALTH CONDITIONS IS MAJOR CAUSE FOR FEMALE-SPECIFIC HEALTH ISSUES            

4.2.2       GROWING EMPHASIS ON PREVENTIVE CARE SERVICES   

4.2.3       INITIATIVES TAKEN TO PROMOTE WOMEN HEALTHCARE               

4.2.4       INCREASE IN R&D ACTIVITIES BY MAJOR PLAYERS FOR WOMEN HEALTH 

4.3          RESTRAINTS       

4.3.1       HIGH COST OF DIAGNOSIS         

4.3.2       HIGH COST OF TREATMENT        

4.4          OPPORTUNITIES              

4.4.1       EARLY DIAGNOSIS OF THE WOMEN HEALTH DISEASES   

4.4.2       RISING AWARENESS FOR WOMEN HEALTH IN EMERGING NATIONS         

4.5          CHALLENGE      

4.5.1       CHALLENGES TO ACCESSING CARE          

5              MARKET FACTOR ANALYSIS         

5.1          PORTERS FIVE FORCES MODEL  

5.1.1       BARGAINING POWER OF SUPPLIERS       

5.1.2       BARGAINING POWER OF BUYERS             

5.1.3       THREAT OF NEW ENTRANTS        

5.1.4       THREAT OF SUBSTITUTES             

5.1.5       INTENSITY OF RIVALRY  

5.2          VALUE CHAIN ANALYSIS               

5.2.1       RESEARCH & DEVELOPMENT (R&D)         

5.2.2       OPERATIONS     

5.2.3       COMMERCIAL OPERATIONS AND DISTRIBUTION & PHARMACIES               

5.2.4       CONSUMERS     

6              GLOBAL WOMEN HEALTHCARE MARKET, BY INDICATION              

6.1          INTRODUCTION              

6.2          POSTMENOPAUSAL OSTEOPOROSIS       

6.3          INFERTILITY       

6.4          REPRODUCTIVE HEALTH MANAGEMENT               

6.5          POLYCYSTIC OVARY SYNDROME               

6.6          GYNECOLOGIC CANCER               

6.7          OTHER INDICATIONS     

7              GLOBAL WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT  

7.1          INTRODUCTION              

7.2          DIAGNOSIS        

7.3          TREATMENT       

8              GLOBAL WOMEN HEALTHCARE MARKET, BY END USER  

8.1          INTRODUCTION              

8.2          HOSPITALS & CLINICS   

8.3          GYNECOLOGY CENTERS               

8.4          RESEARCH INSTITUTES  

8.5          OTHER END USER           

9              GLOBAL WOMEN HEALTHCARE MARKET, BY REGION       

9.1          INTRODUCTION              

9.2          NORTH AMERICA             

9.2.1       THE U.S.              

9.2.2       CANADA              

9.3          EUROPE              

9.3.1       GERMANY          

9.3.2       FRANCE               

9.3.3       UK         

9.3.4       ITALY    

9.3.5       SPAIN   

9.3.6       REST OF EUROPE             

9.4          ASIA-PACIFIC     

9.4.1       JAPAN  

9.4.2       CHINA  

9.4.3       INDIA   

9.4.4       REPUBLIC OF KOREA      

9.4.5       REST OF ASIA-PACIFIC    

9.5          MIDDLE EAST & AFRICA

9.5.1       UAE       

9.5.2       SAUDI ARABIA  

9.5.3       EGYPT  

9.5.4       REST OF MIDDLE EAST & AFRICA               

10           COMPETITIVE LANDSCAPE          

10.1        INTRODUCTION              

11           COMPANY PROFILE        

11.1        ALLERGAN PLC.

11.1.1     OVERVIEW          

11.1.2     PRODUCT OVERVIEW    

11.1.3     FINANCIALS       

11.1.4     KEY DEVELOPMENTS     

11.1.5     SWOT ANALYSIS               

11.2        AMGEN               

11.2.1     COMPANY OVERVIEW    

11.2.2     PRODUCT/BUSINESS SEGMENT OVERVIEW          

11.2.3     FINANCIAL OVERVIEW   

11.2.4     KEY DEVELOPMENT        

11.2.5     SWOT ANALYSIS               

11.3        BAYER AG           

11.3.1     OVERVIEW          

11.3.2     PRODUCT/BUSINESS SEGMENT OVERVIEW          

11.3.3     FINANCIAL UPDATES     

11.3.4     KEY DEVELOPMENTS     

11.3.5     SWOT ANALYSIS               

11.4        BECTON, DICKINSON AND COMPANY    

11.4.1     OVERVIEW          

11.4.2     PRODUCT/BUSINESS SEGMENT OVERVIEW          

11.4.3     FINANCIAL UPDATES     

11.4.4     KEY DEVELOPMENTS     

11.4.5     SWOT ANALYSIS               

11.5        ELI LILLY COMPANY       

11.5.1     COMPANY OVERVIEW    

11.5.2     PRODUCT/BUSINESS SEGMENT OVERVIEW          

11.5.3     FINANCIAL OVERVIEW   

11.5.4     KEY DEVELOPMENT        

11.5.5     SWOT ANALYSIS               

11.6        MERCK & CO., INC.          

11.6.1     OVERVIEW          

11.6.2     PRODUCT OVERVIEW    

11.6.3     FINANCIALS       

11.6.4     KEY DEVELOPMENTS     

11.6.5     SWOT ANALYSIS               

11.7        PFIZER INC.        

11.7.1     OVERVIEW          

11.7.2     PRODUCT OVERVIEW    

11.7.3     FINANCIALS       

11.7.4     KEY DEVELOPMENTS     

11.7.5     SWOT ANALYSIS               

11.8        TEVA PHARMACEUTICAL INDUSTRIES LTD            

11.8.1     COMPANY OVERVIEW    

11.8.2     PRODUCT OVERVIEW    

11.8.3     FINANCIAL OVERVIEW   

11.8.4     KEY DEVELOPMENTS     

11.8.5     SWOT ANALYSIS               

                               

                               

                               

 

 

List of Tables                    

                               

TABLE 1                GLOBAL WOMEN HEALTHCARE MARKET, BY INDICATION, 2014-2023 (USD MILLION)        

TABLE 2                POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY REGION, 2014-2023 (USD MILLION)       

TABLE 3                INFERTILITY MARKET, BY REGION, 2014-2023 (USD MILLION)       

TABLE 4                REPRODUCTIVE HEALTH MANAGEMENT MARKET, BY REGION, 2014-2023 (USD MILLION)               

TABLE 5                POLYCYSTIC OVARY SYNDROME MARKET, BY REGION, 2014-2023 (USD MILLION)

TABLE 6                GYNECOLOGIC CANCER MARKET, BY REGION, 2014-2023 (USD MILLION)

TABLE 7                OTHER INDICATIONS MARKET, BY REGION, 2014-2023 (USD MILLION)     

TABLE 8                GLOBAL WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2014-2023  (USD MILLION)           

TABLE 9                DIAGNOSIS MARKET, BY REGION, 2014-2023 (USD MILLION)        

TABLE 10              TREATMENT MARKET, BY REGION, 2014-2023 (USD MILLION)       

TABLE 11              GLOBAL WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)             

TABLE 12              HOSPITALS & CLINICS MARKET, BY REGION, 2014-2023 (USD MILLION)   

TABLE 13              GYNECOLOGY CENTERS MARKET, BY REGION, 2014-2023 (USD MILLION)

TABLE 14              RESEARCH INSTITUTES MARKET, BY REGION, 2014-2023 (USD MILLION)  

TABLE 15              OTHER END USER MARKET, BY REGION, 2014-2023 (USD MILLION)            

TABLE 16              GLOBAL WOMEN HEALTHCARE MARKET, BY REGION, 2014-2023 (USD MILLION) 

TABLE 17              NORTH AMERICA WOMEN HEALTHCARE MARKET, BY COUNTRY, 2014-2023 (USD MILLION)            

TABLE 18              NORTH AMERICA WOMEN HEALTHCARE MARKET, BY INDICATION, 2014-2023 (USD MILLION)       

TABLE 19              NORTH AMERICA WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)               

TABLE 20              NORTH AMERICA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)           

TABLE 21              U.S. WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)  

TABLE 22              U.S. WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)      

TABLE 23              U.S. WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)      

TABLE 24              CANADA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)         

TABLE 25              CANADA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023  (USD MILLION)            

TABLE 26              CANADA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)            

TABLE 27              EUROPE LANCET MARKET, BY COUNTRY, 2014-2023 (USD MILLION)          

TABLE 28              EUROPE WOMEN HEALTHCARE MARKET, BY INDICATION, 2014-2023 (USD MILLION)        

TABLE 29              EUROPE WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2014-2023  (USD MILLION)           

TABLE 30              EUROPE WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)             

TABLE 31              GERMANY WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)     

TABLE 32              GERMANY WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)         

TABLE 33              GERMANY WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)         

TABLE 34              FRANCE WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)          

TABLE 35              FRANCE WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023  (USD MILLION)             

TABLE 36              FRANCE WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)             

TABLE 37              UK WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)    

TABLE 38              UK WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)        

TABLE 39              UK WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)       

TABLE 40              ITALY WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)               

TABLE 41              ITALY WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)   

TABLE 42              ITALY WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)  

TABLE 43              SPAIN WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)              

TABLE 44              SPAIN WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)  

TABLE 45              SPAIN WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 

TABLE 46              REST OF EUROPE WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)        

TABLE 47              REST OF EUROPE WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)               

TABLE 48              REST OF EUROPE WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)           

TABLE 49              ASIA-PACIFIC LANCET MARKET, BY COUNTRY, 2014-2023 (USD MILLION) 

TABLE 50              ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY INDICATION, 2014-2023 (USD MILLION)               

TABLE 51              ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)   

TABLE 52              ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)   

TABLE 53              JAPAN WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)             

TABLE 54              JAPAN WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 

TABLE 55              JAPAN WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 

TABLE 56              CHINA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)             

TABLE 57              CHINA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023  (USD MILLION)

TABLE 58              CHINA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 59              INDIA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)              

TABLE 60              INDIA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)  

TABLE 61              INDIA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 

TABLE 62              REPUBLIC OF KOREA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023  (USD MILLION)

TABLE 63              REPUBLIC OF KOREA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)            

TABLE 64              REPUBLIC OF KOREA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)    

TABLE 65              REST OF ASIA-PACIFIC WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023  (USD MILLION)              

TABLE 66              REST OF ASIA-PACIFIC WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)            

TABLE 67              REST OF ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)  

TABLE 68              MIDDLE EAST & AFRICA LANCET MARKET, BY COUNTRY, 2014-2023 (USD MILLION)            

TABLE 69              MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY INDICATION, 2014-2023 (USD MILLION)          

TABLE 70              MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)            

TABLE 71              MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)              

TABLE 72              UAE WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)  

TABLE 73              UAE WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)      

TABLE 74              UAE WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)     

TABLE 75              SAUDI ARABIA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)             

TABLE 76              SAUDI ARABIA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 

TABLE 77              SAUDI ARABIA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION) 

TABLE 78              EGYPT WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)             

TABLE 79              EGYPT WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION) 

TABLE 80              EGYPT WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 81              REST OF MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET BY INDICATION, 2014-2023 (USD MILLION)               

TABLE 82              REST OF MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2014-2023 (USD MILLION)

TABLE 83              REST OF MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY END USER, 2014-2023 (USD MILLION)               

TABLE 84              AMGEN: KEY DEVELOPMENT      

TABLE 85              ELI LILLY COMPANY: KEY DEVELOPMENT              

TABLE 86              PFIZER: PRODUCT OVERVIEW     

TABLE 87              PFIZER: KEY DEVELOPMENTS      

TABLE 88              TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS

                               

                              

LIST OF FIGURES           

                               

FIGURE 1             GLOBAL WOMEN HEALTHCARE MARKET: MARKET STRUCTURE   

FIGURE 2             RESEARCH PROCESS       

FIGURE 3             GLOBAL WOMEN HEALTHCARE MARKET: PORTERS FIVE FORCES MODEL

FIGURE 4             GLOBAL WOMEN HEALTHCARE MARKET: VALUE CHAIN ANALYSIS             

FIGURE 5             GLOBAL WOMEN HEALTHCARE MARKET, BY INDICATION, 2016 & 2023 (USD MILLION)    

FIGURE 6             GLOBAL WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2016 & 2023 (USD MILLION)        

FIGURE 7             GLOBAL WOMEN HEALTHCARE MARKET, BY END USER, 2016 & 2023 (USD MILLION)         

FIGURE 8             GLOBAL WOMEN HEALTHCARE MARKET, BY REGION, 2016 & 2023 (USD MILLION)             

FIGURE 9             NORTH AMERICA WOMEN HEALTHCARE MARKET, BY COUNTRY, 2016 (%)               

FIGURE 10           EUROPE WOMEN HEALTHCARE MARKET, BY COUNTRY, 2016 (%)

FIGURE 11           ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY COUNTRY, 2016 (%)       

FIGURE 12           MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY COUNTRY, 2016 (%)  

FIGURE 13           GLOBAL WOMEN HEALTHCARE MARKET: COMPETITIVE LANDSCAPE        

FIGURE 14           ALLERGAN PLC: FINANCIAL REVENUE     

FIGURE 15           ALLERGAN PLC: SEGMENTAL REVENUE  

FIGURE 16           AMGEN: RECENT FINANCIAL       

FIGURE 17           AMGEN: GEOGRAPHIC REVENUE MIX     

FIGURE 18           AMGEN: SWOT ANALYSIS             

FIGURE 19           BAYER AG: FINANCIAL REVENUE               

FIGURE 20           BAYER AG: SEGMENTAL REVENUE            

FIGURE 21           BAYER AG: GEOGRAPHICAL REVENUE     

FIGURE 22           BAYER AG: SWOT ANALYSIS         

FIGURE 23           BECTON, DICKINSON AND COMPANY: FINANCIAL REVENUE        

FIGURE 24           BECTON, DICKINSON AND COMPANY: SEGMENTAL REVENUE     

FIGURE 25           BECTON, DICKINSON AND COMPANY: GEOGRAPHICAL REVENUE              

FIGURE 26           BECTON, DICKINSON & COMPANY: SWOT ANALYSIS        

FIGURE 27           ELI LILLY COMPANY: RECENT FINANCIAL               

FIGURE 28           ELI LILLY COMPANY: BUSINESS REVENUE MIX (2015)       

FIGURE 29           ELI LILLY COMPANY: GEOGRAPHIC REVENUE MIX             

FIGURE 30           ELI LILLY COMPANY: SWOT ANALYSIS     

FIGURE 31           MERCK & CO., INC.: FINANCIAL REVENUE              

FIGURE 32           MERCK & CO., INC.: SEGMENTAL REVENUE           

FIGURE 33           MERCK & CO., INC.: GEOGRAPHIC REVENUE        

FIGURE 34           PFIZER: FINANCIAL REVENUE     

FIGURE 35           PFIZER: SEGMENTAL REVENUE  

FIGURE 36           PFIZER: GEOGRAPHIC REVENUE

FIGURE 37           PFIZER: SWOT ANALYSIS               

FIGURE 38           TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT FINANCIALS 

FIGURE 39           TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL MIX, 2016 (%)             

FIGURE 40           TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS, 2016 (%)        

FIGURE 41           TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS         

                               

captcha
Please enter code
captcha
Please enter code

Purchase this Market Research Report

Add To Cart

Market Research Videos

REPORT YOU MIGHT BE INTERESTED

Contact Us

Email Us at: salesteam@marketresearchfuture.com | Reach Us at: + (646) 845 9349 (US), +44 208 133 9349 (uk)